Lack of congressional funding has forced the US Food and Drug Administration to scale back its Cybersecurity Medical Safety Analysis Board proposal. Instead of launching the public-private partnership board that would advise the agency on emerging and ongoing cybersecurity threats this year, the agency has only gone as far as putting together a small multi-stakeholder team to help develop the program, which may never happen.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?